Cetuximab, a chimeric monoclonal antibody againts epidermal growth factor receptor (EGFR), is increasingly used to treat tumors that overexpress this receptor as squamous cell cancer of the head and neck (SCCHN), colon and non-small-cell lung cancers. The most common side effects of anti-EGFR are acneiform rash, xerosis, paronychia, teleangiectasia and itch. We report the unusual case of a patient with SCCHN in whom treatment with cetuximab led to development of multiple cutaneous abscesses.
Ricci, F., Guerriero, C., Paradisi, A., Fossati, B., Micciche', F., Valentini, V., Capizzi, R., Multiple abscesses in a patient treated with cetuximab, <<EUROPEAN JOURNAL OF DERMATOLOGY>>, 2013; 23 (1): 103-104. [doi:10.1684/ejd.2012.1889] [http://hdl.handle.net/10807/42038]
Multiple abscesses in a patient treated with cetuximab
Ricci, Francesco;Guerriero, Cristina;Paradisi, Andrea;Fossati, Barbara;Micciche', Francesco;Valentini, Vincenzo;Capizzi, Rodolfo
2013
Abstract
Cetuximab, a chimeric monoclonal antibody againts epidermal growth factor receptor (EGFR), is increasingly used to treat tumors that overexpress this receptor as squamous cell cancer of the head and neck (SCCHN), colon and non-small-cell lung cancers. The most common side effects of anti-EGFR are acneiform rash, xerosis, paronychia, teleangiectasia and itch. We report the unusual case of a patient with SCCHN in whom treatment with cetuximab led to development of multiple cutaneous abscesses.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
